bivatuzumab mertansine

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Breast NeoplasmsCarcinoma, Squamous CellHead and Neck Neoplasms

Phase 1

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

CompletedNCT02254005

Boehringer IngelheimBreast Neoplasms

Start: 2002-10-01Updated: 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

TerminatedNCT02254031

Boehringer IngelheimBreast Neoplasms

Start: 2003-07-01Updated: 2023-10-24

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

CompletedNCT02254018

Boehringer IngelheimHead and Neck Neoplasms

Start: 2002-09-01Updated: 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

TerminatedNCT02254044

Boehringer IngelheimCarcinoma, Squamous Cell

Start: 2003-10-31Updated: 2014-10-01